A Phase 2, Randomized, Double-blind,Placebo Controlled, Parallel Group Study to Assess Efficacy, Safety, and Pharmacokinetics (PK) of QLM3003 Ointment in Participants With Mild or Moderate Atopic Dermatitis
Latest Information Update: 17 Mar 2025
At a glance
- Drugs QLM 3003 (Primary)
- Indications Atopic dermatitis
- Focus Therapeutic Use
- Sponsors Qilu Pharmaceutical
Most Recent Events
- 12 Mar 2025 Status changed from not yet recruiting to completed.
- 04 Oct 2023 New trial record